Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR.
抗 EGFR 疗法可以克服由 EGFR 激活介导的对第三代 ALK 酪氨酸激酶抑制剂劳拉替尼的获得性耐药性
期刊:Acta Pharmacologica Sinica
影响因子:8.4
doi:10.1038/s41401-025-01511-z
Hu Chen, Lu Cong-Hua, Zheng Jie, Kang Jun, Huang Dai-Juan, He Chao, Liu Yi-Hui, Liu Zhan-Rui, Wu Di, Dou Yuan-Yao, Zhang Yi-Min, Lin Cai-Yu, Han Rui, He Yong
